KM Research Hub
← 返回论文库
部分完成 入排:符合 图源:可得 入排置信度 0.98

Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.

Jung-Min Lee, Mark F Brady, Austin Miller, Richard G Moore, Helen MacKay, Leah McNally, Jayanthi Lea, Daron Street, Stephanie Lheureux, Megan E McDonald, Linda R Duska, Guilherme Cantuaria, Juraj Kavecansky, Charles A Leath, Matthew Powell, Mark G Cadungog, Peter G Rose, Yong-Man Kim, Helen Q Huang, Michèle Provencher, Lari B Wenzel, Michael A Bookman, Elise C Kohn, Angeles Alvarez Secord

J Clin Oncol 42(36) 4305-4316

PMID39361946
PMCIDPMC11652233
DOI10.1200/JCO.24.00683
发表日期2024-10-03
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

PURPOSE: We assessed the efficacy of cediranib, olaparib, and cediranib/olaparib compared with standard-of-care chemotherapy (SOC) in platinum-resistant or platinum-refractory epithelial ovarian cancer (PROC). PATIENTS AND METHODS: NRG-GY005 is an open-label, four-arm, phase II/III superiority trial enrolling patients with high-grade serous/endometrioid PROC and one to three previous therapies. Key exclusion criteria included previous receipt of poly(ADP-ribose) polymerase inhibitor or receipt of antiangiogenic therapy in the recurrent setting. Treatment arms (SOC [once weekly paclitaxel, topotecan, or pegylated liposomal doxorubicin], cediranib, olaparib, or cediranib/olaparib) were equally randomized. A preplanned interim futility analysis on the basis of progression-free survival (PFS) selected treatment arms to advance to phase III. PFS and overall survival (OS) were phase III coprimary end points, with hierarchical testing of PFS followed by OS to preserve type 1 error control, designed to have 90% power for a 0.625 PFS hazard ratio (HR). OS was tested after PFS in the multiple hierarchical testing procedure. Secondary end points included objective response rate (ORR) and patient-reported outcomes. RESULTS: Five hundred sixty-two eligible patients were enrolled for phase II/III. Three arms met PFS criteria to carry forward to phase III (SOC, cediranib/olaparib, and cediranib). Median PFS was 3.4, 5.2, and 4 months with SOC, cediranib/olaparib, and cediranib, respectively, with a median follow-up duration of 42.2 months. PFS HR estimates for cediranib/olaparib and cediranib (v SOC) were 0.796 (98.3% CI, 0.597 to 1.060) and 0.972 (98.3% CI, 0.726 to 1.300), respectively. Median OS was 13.6, 12.8, and 10.5 months, and of 443 patients with measurable disease, ORR was 8.6%, 24.7%, and 13.1% for SOC, cediranib/olaparib, and cediranib, respectively. No new safety signals were identified. In patients receiving cediranib/olaparib, no statistically significant difference was observed on the NFOSI-DRS-P subscale compared with SOC (98.3% CI, -1.3 to 1.5, P = .8725). CONCLUSION: The cediranib-containing arms demonstrated clinical activity on the basis of PFS but were not superior compared with SOC.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure A2

online only: Progression-free survival by randomized treatment (Phase II study).

Progression-Free_Survival_by_Randomized_Treatment_-_Phase_2_Subjects_Only

Progression-Free Survival

Figure A2 · Panel Progression-Free_Survival_by_Randomized_Treatment_-_Phase_2_Subjects_Only

quality_warning 待 EXE 对齐 预期 4 条 已提取 3 条

Panel Progression-Free_Survival_by_Randomized_Treatment_-_Phase_2_Subjects_Only 是同一 Figure A2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 4 条,实际恢复 3 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure A1online only: NRG-GY005 phase II/III study design.
非 KM Figure
Figure 1.Consort diagram * One patient was continuing to receive cediranib when the data were frozen. AE, adverse event; ITT, intention-to-treat.
非 KM Figure
Figure 2.Progression-free survival and Overall survival by randomized treatment. Distributions were estimated utilizing the Kaplan-Meier method for progression-free survival (PFS) (A) and overall survival (OS) (B) by investigator assessment. Hazard ratios (HRs) are estimated with a proportional hazards model stratified by platinum-refractory disease status (yes vs no) and prior angiogenic therapy (yes vs no). The confidence intervals (CIs) are adjusted to provide 95% simultaneous coverage for the study’s original 3 treatment comparisons. The P-values are adjusted for multiple comparisons for PFS. No P-values are provided for OS because testing each of these null hypotheses was conditioned on first rejecting hypothesis concerning PFS.
非 KM Figure
Figure 3.Forest plot of Progression-free survival and Overall survival by subgroups Hazard ratios (HRs) and confidence intervals (CIs) are estimated with two separate proportional hazards models. The first model includes indicators for treatment assignment, platinum-refractory disease status (yes vs no) and the interaction between treatments and refractory disease status. The second model includes indicators for treatment assignment, prior angiogenic therapy (yes vs no) and the interaction between treatments and prior angiogenic therapy. These analyses are considered exploratory and no specific hypotheses are tested. The 98.7% CIs are plotted to provide 95% simultaneous coverage for HRs comparing an experimental treatment arm to the standard non-platinum chemotherapy arm over the 4 stratification levels. Ced, cediranib; Olap, olaparib.
非 KM Figure
Figure 4.Patient-reported mean NFOSI-DRS-P subscale scores over time. Larger scores suggest a better or preferable state of health. Least squares means differences are estimated from a fitted linear mixed model after adjusting for assigned study treatment, age at enrollment, initial performance status, pretreatment PRO score, and assessment time. C, cediranib; O, olaparib; Chemo, chemotherapy.
非 KM Figure